The objective was to project incremental cost differences between [IV Truxima] and [SC-Rituxan] over 1 year for a hypothetical 5-million-member US healthcare insured (Medicare) population.
Sizeable savings per patient with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) were anticipated by a Medicare savings model.
A model of rituximab use that involved transitioning a portion of patients to intravenous rituximab biosimilar (Truxima) from a subcutaneous originator rituximab (Rituxan) formulation demonstrated savings of $2359 to $8186 per patient with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL), investigators reported at this year's American Society of Clinical Oncology meeting.
Truxima is a CD20-directed monoclonal antibody and was the first of 3 rituximab biosimilars approved in the United States.
Investigators based their savings analysis on a 5-million-member insured population (Medicare) in which 972 patients would be treated for NHL or CLL during a 1-year span. Of those patients, 49 would receive subcutaneous rituximab/hyaluronidase (SC-R). For purposes of the study, investigators assumed that 25% of the 49 patients (n = 13) would receive intravenous biosimilar treatment (IV-R-BIOSIM).
The 1-year model factored in drug and administration costs and assumed efficacy and safety would be equivalent between the 2 cohorts. For the IV-R-BIOSIM dosing, the investigators assumed body surface area of 1.8m2.
The objective was to project incremental cost differences between [IV Truxima] and [SC-Rituxan] over 1 year for a hypothetical 5-million-member US healthcare insured (Medicare) population.
They also assumed annual dose counts (with either IV-R-BIOSIM or SC-R) of 10 for untreated follicular lymphoma (FL) with maintenance; 8, untreated FL without maintenance, relapsed/refractory FL, or untreated diffuse large B-cell lymphoma; and 6, CLL. Duration of IV-R-BIOSIM infusion was assumed to be 3 hours. SC-R costs included an initial IV Rituxan dose.
For the 13 patients who received the hypothetical IV-R-BIOSIM dosing, estimated total 1-year savings were $57,864. The investigators said their budget impact model was most sensitive to low or high body surface area dosing and the proportion of patients with CLL.
“These findings demonstrate the potential economic benefits of IV-R-BIOSIM vs SC-R that may result in expanded access to rituximab therapy,” they said.
Reference
James E, Trautman H, McBride A, Choudhry A, Thompson S. US budget impact analysis of an intravenous rituximab biosimilar versus subcutaneous rituximab for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Presented at: ASCO 2021; June 3-7, 2021. Abstract e18821.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.